Oral Mucositis Market Report 2026

Oral Mucositis Market Overview

• Oral Mucositis market size has reached to $1.55 billion in 2025 • Expected to grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Cancer Prevalence Fuels Demand For Treatment Solutions • Market Trend: Advancements In Cryotherapy For Managing Chemotherapy Side Effect • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Mucositis Market?

Oral mucositis is a condition characterized by the inflammation and ulceration of the mucous membranes lining the mouth. It is commonly seen as a side effect of cancer treatments particularly chemotherapy and radiation therapy, which damage the rapidly dividing cells of the oral mucosa. The main indications for the oral mucositis are chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Chemotherapy-induced oral mucositis occurs when chemotherapy drugs harm the rapidly dividing cells in the mouth’s lining, resulting in painful ulcers and inflammation. The various products are available in solid dosage form and liquid dosage form. The various treatments comprise palifermin, amifostine, chlorhexidine, sucralfate, avasopasem, and dusquetide. These are distribution channels through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized in various end users such as hospitals, dental clinics, oncology hospitals, and research institutes.

What Is The Oral Mucositis Market Growth Forecast?

The oral mucositis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing investment in oncology supportive care research, increasing approval of novel mucositis therapeutics, rising awareness of early diagnosis and management of oral mucositis, expanding oncology treatment infrastructure in emerging markets, increasing focus on patient-centric cancer care approaches. Major trends in the forecast period include rising incidence of chemotherapy and radiotherapy induced oral mucositis, increasing adoption of targeted and biologic therapies for mucositis management, growing focus on preventive oral care protocols in oncology settings, rising demand for liquid and easy-to-administer dosage forms, increasing clinical emphasis on improving quality of life for cancer patients.

Global Oral Mucositis Market Segmentation

1) By Indication: Chemotherapy, Radiotherapy, Hematopoietic Stem Cell Transplantation 2) By Product Type: Solid Dosage Form, Liquid Dosage Form 3) By Treatment: Palifermin, Amifostine, Chlorhexidine, Sucralfate, Avasopasem, Dusquetide 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Dental Clinics, Oncology Hospitals, Research Institutes Subsegments: 1) By Chemotherapy: High-Dose Chemotherapy-Induced Oral Mucositis, Standard-Dose Chemotherapy-Induced Oral Mucositis 2) By Radiotherapy: Head And Neck Cancer Radiotherapy-Induced Oral Mucositis, Total Body Irradiation-Induced Oral Mucositis 3) By Hematopoietic Stem Cell Transplantation: Autologous Stem Cell Transplantation-Induced Oral Mucositis, Allogeneic Stem Cell Transplantation-Induced Oral Mucositis

What Is The Driver Of The Oral Mucositis Market?

The increasing prevalence of cancer is expected to propel the growth of the oral mucositis market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. The increasing prevalence of cancer cases are due to factors such as aging population, lifestyle changes, environmental exposure, infections and genetic predisposition. Oral mucositis therapy helps cancer patients by alleviating pain, reducing inflammation, preventing secondary infections, and promoting faster healing of oral tissues, ultimately improving their comfort, nutritional intake, and overall quality of life during chemotherapy or radiation therapy. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, reported that, in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections suggest these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Therefore, the increasing prevalence of cancer is driving the growth of oral mucositis industry.

Key Players In The Global Oral Mucositis Market

Major companies operating in the oral mucositis market are Mundipharma International Limited, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, Oragenics Inc., Soligenix Inc., Monopar Therapeutics Inc., EpicentRx, Cellceutix Corporation, GlycoMira Therapeutics Inc., Solasia Pharma KK, 3M Healthcare, GlaxoSmithKline plc, Pfizer Inc., Colgate‑Palmolive Company, CANbridge Pharmaceuticals Inc., Helsinn Healthcare SA, Camurus AB, Norgine B.V., Clinigen Group plc, Alliance Pharma plc, Amag Pharmaceuticals, Izun Pharmaceuticals Corporation, Spherium Biomed, Mission Pharmacal, Access Pharmaceuticals Inc., Otsuka Pharmaceuticals

Global Oral Mucositis Market Trends and Insights

Major companies operating in the oral mucositis market are focusing on developing innovative solutions, such as cryotherapy to reduce the severity and incidence by using cold therapy to minimize damage to oral tissues. Cryotherapy is a medical treatment that uses extreme cold to freeze and destroy abnormal or diseased tissue, used to treat conditions such as warts, tumors, or injuries. For instance, in February 2024, Chemo Mouthpiece LLC, an US-based medical device company, announced chemo mouthpiece device approved by the Food and Drug Administration, a US-based government agency. The chemo mouthpiece is an intraoral ice pack that delivers cryotherapy to the oral cavity of a patient receiving chemotherapy. It proactively manages and treats oral mucositis, a common and painful side effect of chemotherapy.

What Are Latest Mergers And Acquisitions In The Oral Mucositis Market?

In March 2023, EVERSANA, a U.S.-based provider of commercialization services for life-science products, partnered with ChemoMouthpiece, LLC, to support the U.S. launch and commercialization of the Chemo Mouthpiece™, an intraoral cryotherapy device designed to prevent and reduce oral mucositis in chemotherapy patients. Through this collaboration, the companies aim to enhance patient quality of life by mitigating the incidence and severity of oral mucositis, thereby improving adherence to cancer treatment. This partnership highlights the oral mucositis market’s growing emphasis on innovative supportive care solutions and medical devices. ChemoMouthpiece, LLC, a U.S.-based medical-device company.

Regional Outlook

North America was the largest region in the oral mucositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Oral Mucositis Market?

The oral mucositis market consists of revenues earned by entities by providing services such as low-level laser therapy, nutritional support, and cryotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis market also includes sales of mouthwashes and rinses, gels, sprays, or films, topical analgesics and anesthetics, and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Mucositis Market Report 2026?

The oral mucositis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral mucositis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.